Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TNG456 |
| Synonyms | |
| Therapy Description |
TNG456 selectively inhibits PRMT5 in MTAP-null cells, which potentially leads to decreased tumor cell growth (Cancer Res (2025) 85 (8_Supplement_1): 462). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TNG456 | TNG-456|TNG 456 | PRMT5 Inhibitor 21 | TNG456 selectively inhibits PRMT5 in MTAP-null cells, which potentially leads to decreased tumor cell growth (Cancer Res (2025) 85 (8_Supplement_1): 462). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06810544 | Phase Ib/II | Abemaciclib + TNG456 TNG456 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Recruiting | USA | 0 |